"Mannkind Versus Biodel - Mannkind Is A Better Short Term Play"
"I expect Afrezza will be approved and on the market at least a year in advance of VIAject."
"It appears to me that Biodel expects the FDA to require additional trials. If that is the case then I think that pushes the approval date into May of 2011. Biodel's management has also stated they want to launch with the "pen injector" for which Biodel must submit supplemental data."
"Biodel has no manufacturing capability so that pushes launch back another six to nine months. Bottomline is that VIAject could be launched in second quarter 2012."
"Biodel will need additional pipe funding before then."
Just a thought!!!
p.s. Mannkind has everything in place to launch within a few months after approval.
You shorts kill me! Do you think they are sitting around not doing anything. Try $200 next year! Mannkind is an inhaler!!! Even If approved it will take a year or longer to get doctors to buy into the device. The early adopters on the first inhaler did get burned. They will be more cautious and slower to adopt this time around. No long term safety data on this may hurt them
The drug will be approved! IMOP! Biodel is being proactive which in my book is good management and leadership. They want to do it right the first time! So they need to push out the launch. Who cares, they will make billions with this product! Are you an investor or a trader?